More on LNTH
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $99.80 |
|
|||
| Open | $99.95 | ||||
| 52 Wk High | $10.70 | ||||
| 52 Wk Low | $1.76 | ||||
| Day High | $100.12 | ||||
| Day Low | $99.88 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 431,648 | ||||
- Form 8-K Lantheus Holdings, Inc. For: Oct 21
- Form 8-K Lantheus Holdings, Inc. For: Oct 14
- Mizuho Downgrades Lantheus Holdings (LNTH) to Neutral
- Form DEFA14A Lantheus Holdings, Inc.
- Form 8-K Lantheus Holdings, Inc. For: Oct 02
- Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
- Lantheus doses first patient in SPARROW prostate cancer imaging trial
- Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
- FDA approves Lantheus' Bravnetsa as equivalent to Lutathera for GEP-NETs
- Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for
Entities mentioned with LNTH
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- Jefferies & Co | View Related Stories »
- Show More...
